首页|免疫功能低下状态患者罹患新型冠状病毒感染的临床分析

免疫功能低下状态患者罹患新型冠状病毒感染的临床分析

Clinical characteristics of immunocompromised patients infected with COVID-19

扫码查看
目的 分析免疫功能低下状态患者罹患新型冠状病毒感染(coronavirus disease 2019,COVID-19)的临床特征,并与免疫功能正常患者进行比较.方法 采取单中心回顾性观察性研究方法,纳入于2022年12月至2023年10月在北京大学人民医院确诊为COVID-19的213例住院患者,分为免疫功能低下组(102例,47.9%)和免疫功能正常组(111例,52.1%),比较两组间的临床资料.将免疫功能低下组分为死亡组(18例,17.6%)和非死亡组(84例,82.4%),对两组的实验室检查指标进行比较,进一步对其中数据完整的死亡组(10例,9.8%)和非死亡组(36例,35.3%)的淋巴细胞亚群进行差异分析.结果 免疫功能低下组重型、危重型比例以及病死率均高于免疫功能正常组(47.1%vs.40.5%、18.6%vs.9.0%、17.6%vs.9.0%,P<0.05).与免疫功能正常组相比,免疫功能低下组接种疫苗比例偏低(26.5%vs.44.1%,P<0.05),多合并高血压、肾脏疾病及感染(63.7%vs.48.6%、30.4%vs.9.0%、49.0%vs.19.8%,均P<0.05),影像学表现实变影比例、接受抗病毒治疗比例和核酸阳性持续时间均偏高[40.2%vs.18.9%、48.0%vs.30.6%、14(7.0,19.3)d vs.9(7.0,18.0)d,均P<0.05],乳酸脱氢酶、降钙素原、白细胞介素-6和铁蛋白水平显著高于免疫功能正常组(均P<0.05).死亡组的中性粒细胞、C反应蛋白、PCT、IL-6、铁蛋白和D-二聚体水平均显著高于非死亡组(均P<0.05),但淋巴细胞、CD4+T细胞、CD8+T细胞、B细胞计数和血红蛋白均显著低于非死亡组(均P<0.05).结论 免疫功能低下状态患者重型和危重型超过60%,病死率较高,机体清除新冠病毒能力下降.淋巴细胞总数、CD4+T细胞、CD8+T细胞和B细胞减少,降钙素原、铁蛋白和D-二聚体升高提示患者预后不良.
Objective To analyze the clinical features of COVID-19 infection in hospitalized immunocompromised patients in comparison with immunocompetent patients.Methods A single-center retrospective observational study was conducted on 213 inpatients diagnosed with COVID-19 in the Peking University People's Hospital between December 2022 and October 2023.They were divided into an immunocompromised group(102 patients,47.9%)and an immunocompetent group(111 patients,52.1%),and clinical data were compared between the two groups.The immunocompromised group was further divided into death group(18 cases,17.6%)and non-death group(84 cases,82.4%).The differences in laboratory examination findings were compared.Further analysis was performed on the lymphocyte subset differences between the death group(10 patients,9.8%)and the non-death group(36 patients,35.3%)with complete data.Results The proportion of severe and critical cases and the mortality rate,were significantly higher in the immunocompromised group than the immunocompetent group(47.1%vs.40.5%,18.6%vs.9.0%,17.6%vs.9.0%,P<0.05).The immunocompromised group had lower vaccination rate(26.5%vs.44.1%,P<0.05).Hypertension,kidney disease and infections were more common in the immunocompromised group(63.7%vs.48.6%,30.4%vs.9.0%,49.0%vs.19.8%,all P<0.05).CT findings of consolidation(40.2%vs.18.9%),rate of antiviral treatment(48.0%vs.30.6%)and the positive duration of viral nucleic acid[median 14(7.0,19.3)days vs.9(7.0,18.0)days]were higher in the immunocomprised group(all P<0.05).Lactate dehydrogenase(LDH),procalcitonin(PCT),interleukin-6(IL-6)and ferritin were higher in the immunocompromised group than those in the immunocompetent group(all P<0.05).In the death group,neutrophils(NEU),C-reactive protein(CRP),PCT,IL-6,ferritin and D-dimer were higher,while lymphocytes(LY),CD4+T-cells,CD8+T-cells,B-cell counts and hemoglobin(HGB)were significantly lower than those in the non-death group(all P<0.05).Conclusions More than 60%of patients in the immunocompromised group were classified as severe or critical type,with a higher mortality rate and decreased ability to clear severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Decreases in total lymphocytes,CD4+T lymphocytes,CD8+T lymphocytes,and B lymphocytes,along with elevated levels of procalcitonin,ferritin,and D-dimer,indicated poor prognosis.

ImmunityCoronavirus infectionsPneumoniaDisease attributesCOVID-19

李胜男、倪文涛、李冉、陈燕文、高占成

展开 >

北京大学人民医院呼吸与危重症医学科,北京 100044

免疫 冠状病毒感染 肺炎 疾病特征 新型冠状病毒感染

2025

中华结核和呼吸杂志
中华医学会

中华结核和呼吸杂志

北大核心
影响因子:2.692
ISSN:1001-0939
年,卷(期):2025.48(1)